Hematologic Malignancies

Head and Neck Cancers   

Questions discussed in this category


There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?

What field design and dosing is most appropriate? Would you use ISRT or a more extended field? 

Please specify how your institution is allocating resources now or will be soon.

After a nerve sparing parotidectomy, would you offer postoperative radiotherapy? If so, what volume and dose? Would it change your management if the p...

Is there a benefit to IMRT when we treat to relatively low doses (as compared to squamous cell cancers of the head and neck)?


Papers discussed in this category


Clinical lymphoma, myeloma & leukemia, 2014-12

Advances in radiation oncology, 2019

Radiother Oncol, 2008 Feb 20

Int J Radiat Oncol Biol Phys, 2019 Nov 07

Journal of the National Cancer Institute, 2016-06

Pediatrics, 2014 Feb 02

N. Engl. J. Med.,

The Journal of urology, 2018-12

N. Engl. J. Med.,

Lancet Oncol., 2014 Feb 18

NEJM Evidence, 2022 Jun 1

Br J Cancer, 2014 Apr 15

Cancer, 2011-06-15

Eur J Cancer, 2017 Nov 28

N. Engl. J. Med., 2019 Sep 28

Lancet Oncol, 2021 Jan 18

J Clin Oncol, 2021 Apr 19

J Clin Oncol, 2003 Jul 01

JAMA, 2019 Apr 16

Head Neck, 2016 Mar 29

The Lancet. Oncology, 2017-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998 Mar